Synthesis and characterization of molecularly imprinted polymers selective for Erlotinib for lung cancer therapy
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Due to the lack of clinically approved delivery systems for erlotinib (ERL), an epidermal growth factor receptor (EGFR) inhibitor used in the treatment of lung cancer, molecularly imprinted polymers (MIPs) were synthesized. MIPs were chosen due to their specific cavities for the drug and their sustained-release profile. Bioactive monomers (cinchonine and imidazole derivatives) were incorporated to enable ERL specific recognition and synergistic anticancer activity. A series of 12 MIPs was synthesized and characterized by FTIR and SEM. Adsorption assays recognized 1-vinylimidazole and cinchonine formulation (MIP 12) with a retention factor of 41,2% and the highest imprinting factor (IF = 34) among all polymers in the study. Release studies illustrated prolonged release of ERL (~84% in 30 h at pH 7). MIP 12 was non-cytotoxic in lung cancer cells at concentrations up to 90 μg/mL. These results suggest that MIP 12 can be used to improve the pharmacokinetic profile and therapeutic activity of ERL; - Resumo: Síntese e caracterização de polímeros molecularmente impressos selectivos para o Erlotinib para a terapia do cancro do pulmão Neste trabalho sintetizaram-se polímeros molecularmente impressos (MIPs) para o erlotinib (ERL) inibidor do Recetor do Fator de Crescimento Epidérmico (EGFR) por não existirem para ele sistemas de entrega clinicamente aprovados. A escolha dos MIPs deve-se às suas cavidades específicas para o fármaco e ao perfil de libertação prolongada. Monómeros bioativos (derivados da cinchonina e de imidazole) poderão potenciar o reconhecimento específico do ERL e uma atividade anticancerígena sinérgica. Foi sintetizada e caracterizada uma série de 12 MIPs através de FTIR, SEM e DLS. Os ensaios de adsorção identificaram a formulação contendo 1-vinilimidazol e cinchonina (MIP 12) com uma taxa de retenção de 41,2% e o mais elevado fator de impressão entre todos os polímeros estudados. Os estudos demonstraram uma libertação prolongada de ERL (~84% em 30 h a pH 7). O MIP 12 revelou não ser citotóxico em células de cancro do pulmão até 90 μg/mL. Estes resultados sugerem que o MIP 12 pode melhorar o perfil farmacocinético e a atividade terapêutica do ERL.
Fields of Study & Subjects
Analytical chemistry methods development
Nanoparticle-Based Drug Delivery
Advanced Drug Delivery Systems
Publication details
- Journal / source
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
- Publication date
- 11 March 2026
- Language
- EN
- Document type
- Thesis